HealthStream Announces Second Quarter 2021 Results || HealthStream, Inc.

HealthStream Announces Second Quarter 2021 Results

Jul 26, 2021

NASHVILLE, Tenn.--(BUSINESS WIRE)--Jul. 26, 2021-- HealthStream, Inc. (Nasdaq: HSTM), a leading provider of workforce and provider solutions for the healthcare industry, announced today results for the second quarter ended June 30, 2021.

Revenues of $64.8 million in the second quarter of 2021, up 7% from $60.6 million in the second quarter of 2020, more than offsetting a $9.7 million decline in legacy resuscitation revenues.
Operating income of $3.4 million in the second quarter of 2021, down 20% from $4.3 million in the second quarter of 2020.
Net income of $2.4 million in the second quarter of 2021, down 29% from $3.4 million in the second quarter of 2020.
Earnings per share (EPS) of $0.08 per share (diluted) in the second quarter of 2021 compared to $0.11 per share (diluted) in the second quarter of 2020.
Adjusted EBITDA¹ of $14.5 million in the second quarter of 2021, up 20% from $12.1 million in the second quarter of 2020.

¹ Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of adjusted EBITDA to net income and disclosure regarding why we believe adjusted EBITDA provides useful information to investors is included later in this release.

Financial Results:

Second Quarter 2021 Compared to Second Quarter 2020

Revenues for the second quarter of 2021 increased by $4.3 million, or seven percent, to $64.8 million, compared to $60.6 million for the second quarter of 2020.

Revenues from our Workforce Solutions segment were $52.2 million for the second quarter of 2021, an increase of 7% compared to $48.9 million for the second quarter of 2020. The workforce segment achieved this seven percent growth, while overcoming a $9.7 million decline in revenues from the legacy resuscitation business. Revenues from recent acquisitions and growth in other solutions more than offset the lost legacy resuscitation revenues. In addition, workforce revenues also benefited from a $0.5 million increase in professional services revenues, primarily associated with recently acquired businesses.

Revenues from our Provider Solutions segment were $12.7 million for the second quarter of 2021, compared to $11.7 million for the second quarter of 2020. This revenue growth of $1.0 million was primarily attributable to subscription revenues.

Generally accepted accounting principles (GAAP) require companies to write down beginning balances of acquired deferred revenue as part of “fair value” accounting. During the second quarter of 2021, HealthStream reported a reduction of $1.2 million to revenue and operating income and a reduction of $950,000 to net income as a result of deferred revenue write-downs from recent acquisitions. During the second quarter of 2020, HealthStream reported a reduction of $140,000 to revenue and operating income and a reduction of $100,000 to net income as a result of deferred revenue write-downs from acquisitions.

Operating income was $3.4 million for the second quarter of 2021 compared to $4.3 million from the second quarter of 2020. The decrease in operating income was primarily attributable to higher operating expenses and amortization, primarily associated with businesses acquired over the past year.

Net income was $2.4 million in the second quarter of 2021, down 29 percent from $3.4 million in the second quarter of 2020, and EPS was $0.08 per share (diluted) in the second quarter of 2021, compared to $0.11 per share (diluted) for the second quarter of 2020.

Adjusted EBITDA was $14.5 million for the second quarter of 2021, up 20 percent from $12.1 million in the second quarter of 2020.

At June 30, 2021, the Company had cash and cash equivalents and marketable securities of $55.1 million. Capital expenditures incurred during the second quarter of 2021 were $6.9 million.

Year-to-Date 2021 Compared to Year-to-Date 2020

For the first six months of 2021, revenues were $128.3 million, an increase of five percent over revenues of $122.1 million for the first six months of 2020. Operating income for the first six months of 2021 decreased by 42 percent to $6.7 million, compared to $11.5 million for the first six months of 2020. The decrease in operating income was primarily attributable to the $3.4 million one-time favorable contractual adjustment to royalty expense resulting in a reduction to cost of revenues in the first quarter of 2020. Also contributing to the decrease are higher operating expenses primarily associated with acquisitions completed over the past year. Partially offsetting these declines in operating income was a $1.0 million non-recurring, non-cash benefit during the first quarter of 2021 related to the reduction of paid time off (PTO) expense resulting from modifications to the Company’s PTO policy. Net income for the first six months of 2021 decreased to $4.7 million, compared to $10.5 million for the first six months of 2020. Earnings per share were $0.15 per share (diluted) for the first six months of 2021, compared to $0.33 per share (diluted) for the first six months of 2020. Adjusted EBITDA increased by 17 percent to $28.1 million for the first six months of 2021, compared to $24.0 million for the first six months of 2020.

Other Business Updates

At June 30, 2021, we had approximately 4.52 million contracted subscriptions to hStream™, our Platform-as-a-Service technology. hStream technology enables healthcare organizations and their respective workforces to easily connect to and gain value from the growing HealthStream ecosystem of applications, tools, and content.

Financial Outlook for 2021

The Company is updating its guidance for 2021 for the measures set forth below. For a reconciliation of projected adjusted EBITDA, a non-GAAP financial measure defined later in this release, to projected net income (the most comparable GAAP measure) for 2021, see the table included on page 10 of this release.

	Full Year 2021 Guidance
Revenue
Workforce Solutions	$	203.5	-	$	206.5	million
Provider Solutions		49.5	-		50.5	million
Consolidated	$	253.0	-	$	257.0	million

Adjusted EBITDA¹	$	48.0	-	$	50.0	million

Capital Expenditures	$	25.0	-	$	27.0	million

¹ Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net income (the most comparable GAAP measure) is included later in this release.

The Company’s guidance for 2021 as set forth above reflects the Company’s assumptions regarding, among other things, the COVID-19 pandemic as noted below, anticipated integration costs and additional investments in sales, marketing, and product development in 2021 for recently acquired companies, and estimated deferred revenue write-downs of $4.0 to $4.3 million during 2021 related to recent acquisitions, which would result in corresponding reductions to net revenues and operating income during 2021.

The Company’s financial guidance assumes that public health conditions associated with the pandemic and general economic conditions (including conditions impacting healthcare organizations) continue to improve over the course of the year, including that COVID-19 vaccines continue to be successfully distributed and perform according to current expectations and that new variants of the virus, or other unknown variants, do not further impede recovery from the pandemic.

Commenting on second quarter 2021 results, Robert A. Frist, Jr., Chief Executive Officer of HealthStream, said, “We remain laser-focused on growing the Company, which is why we were able to achieve another strong quarter in 2021 with top-line revenues increasing seven percent and adjusted EBITDA increasing 20 percent over the same period last year—offsetting anticipated headwinds presented by both legacy resuscitation revenues and acquisition-related deferred revenue write-downs.”

Frist added, “As we navigate the next two quarters to find a new normal, naturally, some expenses, like travel, will return. Macro workforce trends make recruiting, retention, and hiring more complex for everybody, so we’re working to catch up on our planned hiring. In addition, we are increasing our investment in our newly acquired scheduling businesses in the second half of 2021. Our new guidance reflects all these developments. We are proud of our employees for navigating us forward.”

A conference call with Robert A. Frist, Jr., Chief Executive Officer, Scott A. Roberts, Chief Financial Officer and Senior Vice President, and Mollie Condra, Vice President of Investor Relations and Corporate Communications, will be held on Tuesday, July 27, 2021, at 9:00 a.m. (ET). To listen to the conference, please dial 877-647-2842 (no conference ID needed) if you are calling within the domestic U.S. or Canada. If you are an international caller, please dial 914-495-8564 (no conference ID needed). The conference may also be accessed by going to http://ir.healthstream.com/events.cfm for the simultaneous Webcast of the call, which will subsequently be available for replay. The replay telephone numbers are 855-859-2056 (conference ID #3741799) for U.S. and Canadian callers and 404-537-3406 (conference ID #3741799) for international callers.

Use of Non-GAAP Financial Measures

This press release presents adjusted EBITDA, a non-GAAP financial measure used by management in analyzing the Company’s financial results and ongoing operational performance.

In order to better assess the Company’s financial results, management believes that net income excluding the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses and before interest, income taxes, stock based compensation, depreciation and amortization, changes in fair value of non-marketable equity investments, the de-recognition of non-cash expense resulting from the PTO expense reduction in the first quarter of 2021 and the resolution of a mutual disagreement related to various elements of a past partnership which resulted in a reduction to cost of sales in the first quarter of 2020 (“adjusted EBITDA”) is a useful measure for evaluating the operating performance of the Company because adjusted EBITDA reflects net income adjusted for certain GAAP accounting, non-cash and non-operating items which may not, in any such case, fully reflect the underlying operating performance of our business. We also believe that adjusted EBITDA is useful to investors to assess the Company’s ongoing operating performance and to compare the Company’s operating performance between periods. In addition, beginning in 2021, executive bonuses are based on the achievement of adjusted EBITDA targets.

As noted above, the definition of adjusted EBITDA includes an adjustment for the impact of the deferred revenue write-downs associated with fair value accounting for acquired businesses. Following the completion of any acquisition by the Company, the Company must record the acquired deferred revenue at fair value as defined in GAAP, which may result in a write-down of deferred revenue. If the Company is required to record a write-down of deferred revenue, it may result in lower recognized revenue, operating income, and net income in subsequent periods. Revenue for any such acquired business is deferred and is typically recognized over a one-to-two year period following the completion of any particular acquisition, so our GAAP revenues for this one-to-two year period will not reflect the full amount of revenues that would have been reported if the acquired deferred revenue was not written down to fair value. Management believes that including an adjustment in the definition of adjusted EBITDA for the impact of the deferred write-downs associated with fair value accounting for acquired businesses provides useful information to investors because the deferred revenue write-down recognized in periods after an acquisition may, given the nature of this non-cash accounting impact, cause our GAAP financial results during such periods to not fully reflect our underlying operating performance and thus adjusting for this amount may assist in comparing the Company’s results of operations between periods.

Adjusted EBITDA is a non-GAAP financial measure and should not be considered as a measure of financial performance under GAAP. Because adjusted EBITDA is not a measurement determined in accordance with GAAP, adjusted EBITDA is susceptible to varying calculations. Accordingly, adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies and have limitations as analytical tools.

This non-GAAP financial measure should not be considered a substitute for, or superior to, measures of financial performance, which are prepared in accordance with GAAP. Investors are encouraged to review the reconciliations of adjusted EBITDA to net income (the most comparable GAAP measure), which is set forth below in this release.

About HealthStream

HealthStream (Nasdaq: HSTM) is dedicated to improving patient outcomes through the development of healthcare organizations’ greatest asset: their people. Our unified suite of solutions is contracted by healthcare organizations across the U.S. for workforce development, training & learning management, nurse & staff scheduling, clinical education, credentialing, privileging, provider enrollment, performance assessment, and managing simulation-based education programs. HealthStream’s corporate office is in Nashville, Tennessee. For more information, visit http://www.healthstream.com or call 800-521-0574.

HEALTHSTREAM, INC.
Condensed Consolidated Statements of Income
(In thousands, except per share data)
(Unaudited)

	Three Months Ended					Six Months Ended
	June 30, 2021			June 30, 2020		June 30, 2021			June 30, 2020
Revenues, net	$	64,816		$	60,553	$	128,284		$	122,125
Operating costs and expenses:
Cost of revenues (excluding depreciation and amortization)		22,657			22,935		45,518			43,294
Product development		10,336			7,830		19,861			15,298
Sales and marketing		9,462			8,236		18,481			17,424
Other general and administrative expenses		9,781			10,098		19,391			19,963
Depreciation and amortization		9,149			7,150		18,302			14,599
Total operating costs and expenses		61,385			56,249		121,553			110,578

Operating income		3,431			4,304		6,731			11,547

Other (loss) income, net		(65	)		199		(152	)		1,906

Income before income tax provision		3,366			4,503		6,579			13,453
Income tax provision		925			1,061		1,847			2,920
Net income	$	2,441		$	3,442	$	4,732		$	10,533

Net income per share:
Basic	$	0.08		$	0.11	$	0.15		$	0.33
Diluted	$	0.08		$	0.11	$	0.15		$	0.33

Weighted average shares of common stock outstanding:
Basic		31,553			31,997		31,528			32,166
Diluted		31,616			32,025		31,571			32,191

HEALTHSTREAM, INC.
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)

	June 30,		December 31,
	2021		2020
ASSETS
Current assets:
Cash and cash equivalents	$	49,792	$	36,566
Marketable securities		5,349		9,928
Accounts and unbilled receivables, net		32,454		46,100
Prepaid and other current assets		22,572		22,131
Total current assets		110,167		114,725

Capitalized software development, net		29,918		26,631
Property and equipment, net		19,516		22,218
Operating lease right of use assets, net		26,384		28,081
Goodwill and intangible assets, net		275,604		279,155
Deferred tax assets		974		974
Deferred commissions		22,009		19,907
Other assets		11,730		8,622
Total assets	$	496,302	$	500,313

LIABILITIES AND SHAREHOLDERS’ EQUITY
Current liabilities:
Accounts payable, accrued and other liabilities	$	26,376	$	38,266
Deferred revenue		79,542		81,176
Total current liabilities		105,918		119,442
Deferred tax liabilities		17,898		14,523
Deferred revenue, non-current		1,550		1,603
Operating lease liability, noncurrent		26,911		28,479
Other long-term liabilities		3,646		2,204
Total liabilities		155,923		166,251

Shareholders’ equity:
Common stock		272,783		271,784
Accumulated other comprehensive income		586		1
Retained earnings		67,010		62,277
Total shareholders’ equity		340,379		334,062
Total liabilities and shareholders' equity	$	496,302	$	500,313

HEALTHSTREAM, INC.
Condensed Consolidated Statements of Cash Flows
(In thousands)
(Unaudited)

	Six Months Ended
	June 30,			June 30,
	2021			2020
Operating activities:
Net income	$	4,732		$	10,533
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		18,302			14,599
Stock based compensation		1,398			1,107
Amortization of deferred commissions		4,509			4,254
Deferred income taxes		1,751			2,427
Provision for doubtful accounts		3			351
Loss on equity method investments		133			50
Non-cash paid time off expense		(1,011	)		—
Non-cash royalty expense		—			(3,440	)
Change in fair value of non-marketable equity investments		—			(1,181	)
Other		60			121
Changes in assets and liabilities:
Accounts and unbilled receivables		12,247			(3,759	)
Prepaid and other assets		(7,222	)		(2,006	)
Accounts payable, accrued and other liabilities		(8,839	)		(9,755	)
Deferred revenue		(1,739	)		231
Net cash provided by operating activities		24,324			13,532

Investing activities:
Business combinations, net of cash acquired		(731	)		(21,449	)
Changes in marketable securities		4,526			9,241
Payments to acquire non-marketable equity investments		—			(1,000	)
Payments to acquire equity method investments		(1,750	)		—
Purchases of property and equipment		(2,407	)		(1,268	)
Payments associated with capitalized software development		(10,277	)		(7,619	)
Net cash used in investing activities		(10,639	)		(22,095	)

Financing activities:
Taxes paid related to net settlement of equity awards		(399	)		(373	)
Repurchases of common stock		—			(10,009	)
Payment of cash dividends		(12	)		(31	)
Net cash used in financing activities		(411	)		(10,413	)

Effect of exchange rate changes on cash and cash equivalents		(48	)		(28	)
Net increase (decrease) in cash and cash equivalents		13,226			(19,004	)
Cash and cash equivalents at beginning of period		36,566			131,538
Cash and cash equivalents at end of period	$	49,792		$	112,534

Reconciliation of GAAP to Non-GAAP Financial Measures⁽¹⁾
(In thousands)
(Unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2021			2020			2021			2020
GAAP net income	$	2,441		$	3,442		$	4,732		$	10,533
Deferred revenue write-down		1,231			135			2,852			279
Interest income		(22	)		(237	)		(40	)		(831	)
Interest expense		33			25			65			50
Income tax provision		925			1,061			1,847			2,920
Stock based compensation expense		782			557			1,398			1,107
Depreciation and amortization		9,149			7,150			18,302			14,599
Non-cash paid time off expense		—			—			(1,011	)		—
Change in fair value of non-marketable equity investments		—			(29	)		—			(1,181	)
Non-cash royalty expense		—			—			—			(3,440	)
Adjusted EBITDA	$	14,539		$	12,104		$	28,145		$	24,036

⁽¹⁾ Adjusted EBITDA is a non-GAAP financial measure. A reconciliation of projected adjusted EBITDA to projected net income (the most comparable GAAP measure) is included later in this release.

Reconciliation of GAAP to Non-GAAP Financial Measures
Financial Outlook for 2021
(In thousands)
(Unaudited)

	Low			High
Net income	$	4,200		$	5,200
Deferred revenue write-down		4,300			4,000
Interest income		(100	)		(100	)
Interest expense		100			100
Income tax provision		1,700			2,000
Stock based compensation expense		2,600			3,000
Depreciation and amortization		36,200			36,800
Non-cash paid time off expense		(1,000	)		(1,000	)
Adjusted EBITDA	$	48,000		$	50,000

This press release includes certain forward-looking statements (statements other than solely with respect to historical fact), including statements regarding expectations for financial performance for 2021 as well as the anticipated impact of the COVID-19 pandemic on our financial results, that involve risks and uncertainties regarding HealthStream. These statements are based upon management’s beliefs, as well as assumptions made by and data currently available to management. This information has been, or in the future may be, included in reliance on the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements to be materially different from future results, performance, or achievements expressed or implied by the forward-looking statements, including, without limitation, as the result of developments related to the COVID-19 pandemic, including, without limitation, related to the length and severity of the pandemic; the timing and availability of medical treatments and vaccines with respect to COVID-19; the availability and effectiveness of currently available vaccines and associated levels of vaccination; the spread of potentially more contagious and/or virulent forms of the virus, including possible strains that may be resistant to currently available vaccines; the impact on the pandemic on healthcare organizations; measures we are taking to respond to the pandemic; and the impact of governmental action and regulation in connection with the pandemic (including the CARES Act); as well as risks referenced in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed on February 25, 2021, and in the Company’s other filings with the Securities and Exchange Commission from time to time. Consequently, such forward-looking information should not be regarded as a representation or warranty or statement by the Company that such projections will be realized. Many of the factors that will determine the Company’s future results are beyond the ability of the Company to control or predict. Readers should not place undue reliance on forward-looking statements, which reflect management’s views only as of the date hereof. The Company undertakes no obligation to update or revise any such forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210726005690/en/

Scott A. Roberts
Chief Financial Officer
(615) 301-3182
ir@healthstream.com

Media:
Mollie Condra, Ph.D.
Vice President,
Investor Relations &
Communications
(615) 301-3237
mollie.condra@healthstream.com

Source: HealthStream, Inc.

Solutions

Solutions powered by

Learning & Performance

Learning Management

Products

Video Platform

Products

Reporting & Analytics

Products

Performance & Engagement

Products

Leadership & Upskilling

Products

Quality & Compliance

Regulatory & Compliance

Products

Quality & Safety

Products

Policy Management

Products

Diversity, Equity & Inclusion

Products

Medical Product Training

Products

Reimbursement

Revenue Cycle Education

Products

Resuscitation

Resuscitation Solutions

Products

Clinical Deterioration

Products

Clinical Development

Competency

Products

Onboarding & Placement

Products

Skills & Decision Support

Products

Professional Development

Products

Clinical Quality

Products

Credentialing

Provider Credentialing

Products

Scheduling & Capacity Management

Workforce Engagement

Products

Workforce Scheduling

Products

Operational Intelligence

Products

abaqis®

The S.T.A.B.L.E. Program Online Course

AACN ECCO Essentials of Critical Care Orientation

COVID-19 Support Courses

LATEST & POPULAR

BLOG

BLOG

BLOG

ARTICLE

Learning & Performance

Learning Management

Products

Video Platform

Products

Reporting & Analytics

Products

Performance & Engagement

Products

Leadership & Upskilling

Products

Quality & Compliance

Regulatory & Compliance

Products

Quality & Safety

Products

Policy Management

Products